# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
3-ASR
Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $1...
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $12 ...
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 pri...
Piper Sandler analyst Yasmeen Rahimi maintains Sage Therapeutics (NASDAQ: SAGE) with a Overweight and lowers the price targe...
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
FINANCIAL GUIDANCEBased upon the Company's current operating plan, Sage anticipates that its existing cash, cash equivalent...
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $...